GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success [Seeking Alpha]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Seeking Alpha
Follow Play 15min Summary GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement. GRAIL's revenue growth hinges on FDA approval and insurance reimbursement for Galleri, potentially transforming cancer detection and driving substantial future sales. Yoshiyoshi Hirokawa/DigitalVision via Getty Images In June 2024, GRAIL, Inc. ( NASDAQ: GRAL ) was spun-off from Illumina, Inc. ( ILMN ), which had initially acquired GRAIL as recently as 2021. After struggling to defend the merger with regulatory agencies in the U.S. and Europe for over 3 years, Illumina gave in to setbacks w
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis [Yahoo! Finance]Yahoo! Finance
- Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculturePR Newswire
- China's Failing US Lobby Playbook Puts Tech Companies at Risk [Yahoo! Finance Canada]Yahoo! Finance Canada
- FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer [Yahoo! Finance]Yahoo! Finance
- ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down [Yahoo! Finance]Yahoo! Finance
ILMN
Earnings
- 8/6/24 - Beat
ILMN
Sec Filings
- 9/17/24 - Form 4
- 9/9/24 - Form 4
- 9/9/24 - Form 8-K
- ILMN's page on the SEC website